Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

ABSTRACT: Longitudinal analysis of circulating tumor DNA (ctDNA) has shown promise for monitoring treatment response. However, most current methods lack adequate sensitivity for residual disease detection during or after completion of treatment in patients with nonmetastatic cancer. To address this gap and to improve sensitivity for minute quantities of residual tumor DNA in plasma, we have developed targeted digital sequencing (TARDIS) for multiplexed analysis of patient-specific cancer mutations. In reference samples, by simultaneously analyzing 8 to 16 known mutations, TARDIS achieved 91 and 53% sensitivity at mutant allele fractions (AFs) of 3 in 10⁴ and 3 in 10⁵, respectively, with 96% specificity, using input DNA equivalent to a single tube of blood. We successfully analy

SUBMITTER: McDonald BR 

PROVIDER: S-EPMC7236617 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature